Format

Send to

Choose Destination
Expert Opin Drug Saf. 2016 Jun;15(6):769-75. doi: 10.1517/14740338.2016.1160053. Epub 2016 Mar 16.

Review of pulmonary adverse effects of infliximab therapy in Crohn's disease.

Author information

1
a Pediatric Gastroenterology, The Carman and Ann Adams Department of Pediatrics, Children's Hospital of Michigan , Wayne State University School of Medicine , Detroit , MI , USA.
2
b Department of Emergency Medicine , Wayne State University , Detroit , MI , USA.
3
c Pulmonology, Allergy/Immunology, Cystic Fibrosis and Sleep Medicine (PACS) Division, Department of Pediatrics, Children's Healthcare of Atlanta , Emory University School of Medicine , Atlanta , GA , USA.

Abstract

INTRODUCTION:

Anti-inflammatory therapies are the mainstay for the treatment of inflammatory bowel disease (IBD) in children and adults, including biologics such as infliximab. While there is extensive literature on the general side effects of therapy with infliximab, the data on pulmonary adverse effects remains sparse. This article summarizes the literature related to pulmonary adverse effects of Infliximab therapy in Crohn's Disease.

AREA COVERED:

Published reports of specific pulmonary complications during ongoing therapy with infliximab in patients with IBD were included in the review. A wide variety of infectious and non-infectious complications have been reported with the use of infliximab therapy in IBD.

EXPERT OPINION:

It is important to carefully evaluate respiratory signs and symptoms in patients with IBD, especially those receiving biologic therapies. Besides infectious complications, other non-infectious pulmonary adverse effects associated with the use of infliximab should be considered in patients with IBD. Further, it is important to differentiate primary pulmonary involvement of IBD from pulmonary adverse effects of infliximab therapy. An algorithm for assessing patients with IBD presenting with pulmonary symptoms is provided as a guide for clinicians for medical decision-making.

KEYWORDS:

Adverse effects; Crohn’s Disease; Inflammatory Bowel Disease; Infliximab; Ulcerative Colitis; interstitial lung disease; tumor necrosis factor

PMID:
26923135
DOI:
10.1517/14740338.2016.1160053
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center